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Abstract 
Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation 
in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a 
tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated 
proteins including the SRC family of kinases. Recently our group and others have 
shown that pharmacologic inhibition and genetic knockdown of Bruton’s tyrosine 
kinase (BTK) blocks AML blast proliferation, leukaemic cell adhesion to bone marrow 
stromal cells as well as migration of AML blasts.  The anti-proliferative effects of BTK 
inhibition in human AML are mediated via inhibition of downstream NF-κB pro-
survival signalling however the upstream drivers of BTK activation in human AML 
have yet to be fully characterised. Here we place the FLT3-ITD upstream of BTK in 
AML and show that the BTK inhibitor ibrutinib inhibits the survival and proliferation of 
FLT3-ITD primary AML blasts and AML cell lines. Furthermore ibrutinib inhibits the 
activation of downstream kinases including MAPK, AKT and STAT5. In addition we 
show that BTK RNAi inhibits proliferation of FLT3-ITD AML cells. Finally we report 
that ibrutinib reverses the cyto-protective role of BMSC on FLT3-ITD AML survival. 
These results argue for the evaluation of ibrutinib in patients with FLT3-ITD mutated 
AML.  
3 
 
 
Introduction 
 
Acute myeloid leukaemia (AML) is primarily a disease of the elderly with a median 
age at diagnosis of 72 years. Many elderly patients tolerate current intensive 
cytotoxic chemotherapy regimens poorly and therefore treating the older less fit 
patient with AML presently remains challenging 1. Accordingly despite considerable 
improvements in the outcomes for younger fitter patients with AML over the past 50 
years we have seen little improvement in survival for the majority group of older 
patients with the disease. It is envisaged that improvements in survival for all patients 
with AML will eventually come from targeted therapies that evolve from an improved 
understanding of the biology of the disease.  
 
Drug targeting of pro-tumoral tyrosine kinases has resulted in considerable progress 
in outcomes for patients with chronic myeloid leukaemia 2, chronic lymphocytic 
leukaemia and mantle cell lymphoma 3,4. Furthermore tyrosine kinase inhibition in 
these diseases is associated with a favourable side effect profile, which has 
permitted successful use in both younger and older patients alike. A number of 
receptor and non-receptor tyrosine kinases have been identified as functionally 
important in the biology of acute myeloid leukaemia (AML) 5 6,7. Protein Kinase B 
(AKT), phosphatidylinositol 3-kinase isoform p110delta (P13-K), Signal Transducer 
and Activator of transcription 5 (STAT5), Mitogen-Activated Protein Kinase (MAPK) 
and Bruton’s tyrosine Kinase (BTK), have all been shown to be part of pathways that 
regulate AML survival 8-11. 
 
Various receptor tyrosine kinase mutations have been identified in AML patients10. 
20% of patients with AML are affected by internal tandem duplication (ITD) of the 
juxtamembrane region of the FMS-like tyrosine kinase-3 receptor (FLT3) 12,13 14. The 
activating FLT3-ITD mutations in AML regulate downstream pro-leukaemic pathways 
15 making FLT3 an attractive drugable target in this disease 16. However to date 
drugs targeting FLT3 have demonstrated limited clinical efficacy suggesting that 
FLT3 inhibitors alone are unlikely to be effective 17, and that other downstream 
targets in this pathway may be more relevant.  
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Bruton’s tyrosine kinase (BTK) is a non-receptor tyrosine kinase which is functionally 
important in a spectrum of benign and malignant haematopoietic cells of both the 
lymphoid and myeloid compartments18-22.  Recently the oral BTK inhibitor ibrutinib 
has been shown to inhibit AML blast proliferation, migration and leukaemic cell 
adhesion to bone marrow stromal cells in approximately 80% of primary samples 
tested, leading to the initiation of early phase clinical trials of ibrutinib in AML 9 23. 
The anti-proliferative effects of BTK inhibition in human AML are mediated via 
inhibition of downstream AKT, MAPK, ERK and Nuclear Factor-KappaB (NF-κB) pro-
survival signalling however the upstream drivers of BTK activation in human AML 
have yet to be characterised.  
 
In this study we place BTK activation downstream of mutated FLT3 in primary AML 
cells and furthermore show how inhibition of BTK (by ibrutinib and RNA interference) 
targets FLT3 mutated AML cells by inhibiting cell survival. We also report how 
ibrutinib synergises in combination with daunorubicin, and how ibrutinib functions in 
part by reducing the cyto-protection provided to FLT3-ITD AML cells by bone marrow 
stromal cells. Here we provide a biologic rationale for the targeting of BTK in FLT3 
mutated AML. 
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Materials and methods 
Materials 
Anti-phosphorylated and total FLT3, AKT, BTK, STAT5 and MAPK antibodies were 
purchased from Cell Signalling Technology (Cambridge, MA). Anti-CD34-PE, anti-
CD90-FITC, anti-CD73-PE, anti-CD105-APC antibodies were purchased from 
Miltenyi Biotec (Auburn, CA). Ibrutinib was obtained from Selleck Chemicals. All 
other reagents were obtained from Sigma-Aldrich (St Louis, MO), unless indicated. 
 
Methods 
Cell lines and primary cells. 
The AML-derived cell lines were obtained from the European Collection of Cell 
Cultures and DMSZ where they are authenticated by DNA-fingerprinting.  In the 
laboratory they are used at low passage number for a maximum of 6 months post-
resuscitation, testing regularly for Mycoplasma infection.  AML blasts were obtained 
from patients’ bone marrow or blood following informed consent and under approval 
from the UK National Research Ethics Service (LRECref07/H0310/146).  Moreover, 
all aspects of the study were carried out in accordance with the approved guidelines. 
For primary cell isolation, heparinized blood was collected from patients and human 
peripheral blood mononuclear cells (PBMCs) isolated by Histopaque (Sigma-Aldrich, 
UK) density gradient centrifugation. AML samples that were less than 80% blasts 
were purified using the CD34 positive selection kit.   FLT3-ITD analysis was 
performed by the haemato-oncology diagnostic service (Cambridge University 
hospitals NHS trust, Cambridge) as previously described and 5 patients with FLT3-
ITD and 6 with no FLT3 mutation were selected for this study 14,24.  
 
Human bone marrow stromal cells (BMSC) were isolated from bone marrow 
aspirates of AML patients.  Mononuclear cells were collected by gradient 
centrifugation and plated in growth medium containing RPMI and 20% FBS and 1% 
l-glut. The non-adherent cells were removed after 2 days. When 60%-80% confluent, 
adherent cells were trypsinised and expanded for 3-5 weeks. BMSCs were checked 
for positive expression of CD105, CD73, and CD90 and the lack of expression of 
CD45 and CD34 by flow cytometry as previously described 9.  
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Western immunoblotting. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot 
analyses were performed as described previously. Briefly, whole cell lysates were 
extracted and sodium dodecyl sulfate-polyacrylamide gel electrophoresis separation 
performed 25. Protein was transferred to nitrocellulose and Western blot analysis 
performed with the indicated antisera according to their manufacturer’s guidelines. 
 
Survival and apoptosis assays 
Cells were treated with different doses of ibrutinib then viable numbers measured 
with CellTiter-Glo (Promega, Southampton, UK).  Flow cytometry for measuring 
apoptosis was performed on the Accuri C6 flow cytometer (BD Biosciences, Oxford, 
UK). Samples were collected and stained with annexin- V and propidium Iodide (PI) 
(Abcam), followed by detection. For the AML-BMSC co-cultures AML cell viability 
was measured using flow cytometry.  After exclusion of BMSC by electronic gating 
using negative for CD45 expression the extent of AML cells apoptosis was measured 
using annexin-V.  
 
 
Transfections 
AML cell line transfections were carried out with 1x106 cells using the Amaxa 
Nucleofactor Kit II. Control siRNA and BTK siRNA 1-3 were purchased from 
Invitrogen were transfected in at a concentration of 50nm. For all gene expression 
experiments the cells were incubated for 24 hours post transfection before RNA 
extraction. For the Western blot and cell viability assays AML cell were incubated for 
48 hours post transfection. 
 
RNA extraction and real time PCR (RT-PCR) 
Total RNA was extracted from 1 × 106 cells by use of the Nucleic acid PrepStation 
from Applied Biosystems, according to the manufacturer's instructions. Reverse 
transcription was performed using the RNA PCR core kit (Applied Biosystems). Real-
time PCR primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 
BTK were purchased from Invitrogen. Relative quantitative real-time PCR used 
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SYBR green technology (Roche) on cDNA generated from the reverse transcription 
of purified RNA. After pre-amplification (95°C for 2 minutes), the PCRs were 
amplified for 45 cycles (95°C for 15 seconds and 60°C for 10 seconds and 72°C for 
10 seconds) on a 384-well LightCycler 480 (Roche). Each mRNA expression was 
normalized against GAPDH mRNA expression via use of the standard curve method. 
 
Statistical analyses 
Mann-Whitney test was performed to assess statistical significance from treated 
sample compared to controls. Results with P < 0.05 were considered statistically 
significant (*). Results represent the median and in some instances mean ± SD of 3 
independent experiments. For Western blotting, data are representative images of 3 
independent experiments. 
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Results 
Ibrutinib inhibits survival of FLT3-ITD positive AML blasts and AML cell lines. 
We have previously shown that ibrutinib inhibits factor induced AML blast 
proliferation and downstream AKT and MAPK signalling pathways 9. Here we looked 
to characterise whether FLT3-ITD mutated primary AML and AML cell lines, which 
accounts for approximately 20% of all AML14, responds to BTK inhibition by ibrutinib 
treatment. First we identified 5 AML patients with FLT3-ITD mutation and 6 AML 
patients with no FLT3 mutation. Next we treated the primary AML blast with 
increasing concentrations of ibrutinib for 48 hours followed by analysis of cell 
survival. AML with FLT3-ITD mutations show increased sensitivity to increasing 
doses of ibrutinib compared to non-FLT3 mutated AML (Figure 1A), Similar 
experiments in AML cell lines shows that MV4-11 (FLT3-ITD), but not OCI-AML3 or 
THP-1 (non- FLT3-ITD), have reduced survival in response to increasing 
concentrations of ibrutinib up to a maximum of 5000nM (Figure 1B). Finally we used 
colony forming cell assay to determine the effect to ibrutinib on FLT3-ITD primary 
AML colony formation compared to normal CD34+ HPC and non-FLT3 mutated AML 
blasts. Figure 1C shows that AML with FLT3-ITD showed increased sensitivity to 
ibrutinib compared to normal CD34+ HPC and non-FLT3 mutated AML. 
Supplementary figure 1 shows that our positive control AC220 can also inhibit 
proliferation in MV4-11 and FLT-ITD primary AML. Moreover, AC220 in combination 
with ibrutinib showed no additive inhibitory effect on MV4-11 suggesting that these 
inhibitors are working through the same pathway (supplementary figure 2). To 
confirm the expression of pBTK in human FLT3-ITD AML compared to AML blasts 
without mutation we examined pBTK and total BTK in primary AML and AML cell 
lines.  Figure 1D shows that pBTK is highly expressed in FLT3-ITD AML compared 
to no FLT3-ITD mutation. Furthermore, analysis of pBTK in AML cell lines confirms 
that FLT3-ITD mutated cells have high pBTK expression (Figure 1E). However we 
did observe expression of pBTK in non-FLT3 mutated AML cell lines. Together these 
results suggest that ibrutinib is particularly effective at inhibiting FLT3-ITD mutated 
AML cell survival.  
 
Ibrutinib inhibits downstream signalling in FLT3-ITD AML 
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To determine if ibrutinib inhibits downstream signalling in FLT3-ITD mutated primary 
AML blasts, we compared AML with FLT3-ITD to AML without FLT3-ITD in response 
to increasing concentrations of ibrutinib for 3 h. Figure 2A shows that in primary AML 
associated with FLT3-ITD mutations showed decreased expression of pBTK in 
response to ibrutinib when compared to total BTK expression. Figure 2B shows that 
ibrutinib inhibits downstream phosphorylated proteins, including AKT and MAPK in 
primary AML cells with FLT-ITD. Comparing AML cell lines, MV4-11 (FLT3-ITD) but 
not OCI-AML3 (non-FLT3-ITD) show reduced activity of downstream phosphorylated 
AKT, MAPK and STAT5 in response to ibrutinib treatment (Figure 2C). Moreover, to 
determine if ibrutinib can target FLT3 directly we examined the effect of ibrutinib on 
FLT3 phosphorylation and figure 2C shows that ibrutinib does not target FLT3 
directly. Supplementary Figure 3 shows that AC220 can also inhibit pSTAT5 in MV4-
11 cells. Together, these results confirm that ibrutinib inhibits FLT3 mutation 
associated downstream signalling in FLT3-ITD AML.  
 
Ibrutinib enhances daunorubicin induced apoptosis  
We next examined the effect of ibrutinib in combination with front line AML 
chemotherapy daunorubicin by using increasing concentrations of daunorubicin, 
alone and then in combination with Ibrutinib at 500nM. Figure 3A and B shows that 
ibrutinib enhances daunorubicin induced apoptosis in FLT3-ITD AML cell line but not 
non-FLT3-ITD mutated cell lines. From this observation we hypothesise that in FLT3-
ITD AML ibrutinib may permit a dose reduction in daunorubicin treatment while 
maintaining anti-leukaemic cytotoxicity.   
 
We and others have shown that BMSC provide a level of protection for AML blast 
cells from chemotherapy treatments9,14,23,26 therefore we assessed the efficacy of 
ibrutinib at overcoming this stroma associated cyto-protection in combination with 
daunorubicin treatment. Primary AML blasts (FLT3-ITD) when co-cultured on BMSC 
show increased apoptotic/annexin V positive cells when treated with daunorubicin in 
combination with ibrutinib (Figure 3C). 
 
BTK targeted siRNA inhibits survival of MV4-11 but not OCI-AML3 
It has been reported that ibrutinib has other kinase targets27. Therefore to establish 
an anti-BTK role for ibrutinib in FLT3-ITD AML we evaluated the survival of AML cell 
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lines using BTK KD siRNA experiments. Figure 4A and B show the BTK mRNA and 
protein expression of AML cell lines, after transfection with siRNA targeted to 
different parts of the BTK gene. It shows that BTK siRNA3 and 4 are the most 
effective at BTK gene knockdown in both MV4-11 (FLT3-ITD) cells and OCI-AML3 
(non-FLT3-ITD) mutated cells.  Figure 4C shows that BTK siRNA4 can inhibit 
downstream pAKT in MV4-11 but not OCI-AML3. BTK-KD with BTK siRNA3 and 4 
compared to control siRNA results in decreased cell survival in MV4-11 (FLT3-ITD) 
but not in OCI-AML3 (non-FLT3-ITD) mutated cells (Figure 4D). Finally, in results 
similar to those observed with ibrutinib, BTK-KD with siRNA3 enhanced daunorubicin 
induced cell death (Figure 4E). These data confirm that BTK plays a key role in the 
survival of MV4-11 FLT3-ITD mutated cells. 
 
11 
 
 
Discussion 
The FLT3-ITD mutation is present in circa 20% of patients with AML12-14, and 
furthermore its presence in standard risk cytogenetic AML confers an inferior 
prognosis in response to treatment with intensive cytotoxic chemotherapy 28,29. FLT3 
is a member of the platelet-derived growth factor receptor (PDGF-R) subfamily of 
receptor tyrosine kinases and is functionally important in haematopoietic progenitor 
cells30. Furthermore the FLT3-ITD represents a driver mutation in human AML 31.  
Taken together the FLT3-ITD mutation and its downstream signalling represent a 
valid therapeutic target. 
 
To date a number of FLT3 inhibitors have been assessed in vitro and in vivo. The 
FLT3 inhibitor AC220 (quizartinib) has shown good efficacy in in vitro studies 32. In 
patients with relapsed AML initial response rates appear high (circa 50%) in keeping 
with the biologic importance of this pathway. However results of AC220 in relapsed 
AML have thus far failed to demonstrate significant long-term disease free survival in 
the absence of consolidative allogeneic transplant.  CEP701 (Lestaurhas) has been 
assessed in clinical studies of relapsed AML but likewise clinical responses when 
seen appeared short lived and failed to result in long-term disease free survival 33-35. 
Similarly PKC412 (Midostaurin) exhibits clinical activity in patients with FLT3 
mutation but despite significant numbers of patients with a reducing blast count the 
drug has no patients which have achieved complete response 36.  The limited clinical 
success of FLT3 inhibition to date has been attributed to a failure to achieve 
sufficient FLT3 inhibition in patients. This may be occurring through a number of 
mechanisms including increased plasma clearance of the drug and the presence of 
point mutations in the kinase domain or ATP binding pocket of FLT3, which confer 
drug resistance 17. More potent FLT3 inhibitors are now in development and under 
evaluation for the treatment of AML to see if these results can be improved upon. 
However an alternative strategy would be to target other kinases downstream of the 
FLT3 mutations.  
 
BTK is a non-receptor tyrosine kinase that belongs to the Tec kinase family and 
plays an important role in both benign and malignant cells of the haematopoietic 
system 9,37-40. BTK is an essential mediator of B-cell receptor (BCR) signalling and is 
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therefore fundamental to the development of normal B-cells 41,42. However other 
receptors including Toll-like receptors (TLRs) also appear to signal through BTK in 
some non-lymphoid cells 43.  In the BCR signalling pathway BTK is positioned early 
on along with three other non-receptor tyrosine kinases PI3-K, LYN and SYK 44. LYN 
and SYK have been shown to activate BTK in B cells 45,46. Furthermore LYN and 
SYK have also been identified as important in AML survival signalling 5,47 and BTK 
activation via phosphorylation is evident in the blasts from the majority of patients 
with AML 9. In addition, it is becoming apparent that ibrutinib inhibits kinases other 
than BTK including mutant epidermal growth factor receptor and interleukin-2-
inducible T-cell kinase 48, 49. However, we and others have shown that BTK KD using 
siRNA or shRNA mimics the ibrutinib effects in AML 50. Therefore, with the advent of 
ibrutinib, BTK is a drugable target in AML however the upstream drivers of BTK 
activation in AML are presently not well characterised.  
 
In this study we demonstrate BTK is activated downstream of the FLT3-ITD in AML 
and that BTK inhibition targets FLT3-ITD induced survival and proliferation pathways 
including AKT, STAT5 and MAPK. In addition when we used the FLT3 inhibitor 
AC220 in combination with ibrutinib there was no additive effect on AML survival, 
thus supporting the hypothesis that these two inhibitors are working on the same 
survival pathway/s in FLT3-ITD AML. Furthermore we have shown that treatment of 
FLT3-ITD AML with ibrutinib or BTK knockdown in combination with daunorubicin 
increases tumour apoptosis over daunorubicin alone. We show in vitro that ibrutinib 
permits dose reduction of daunorubicin to achieve a given rate of cytotoxicity. As 
daunorubicin toxicity presents a clinical challenge in the treatment of older less fit 
patients with AML ibrutinib may allow protocols in the future to dose reduce 
daunorubicin while maintaining clinical efficacy but improving tolerability. This may 
result in effective but reduced dose daunorubicin containing treatment regimens 
being offered with curative intent to patients not currently deemed fit enough for a 
standard daunorubicin/ cytarabine intensive schedule.  
 
Resistance to FLT3 inhibitors can occur through mutations at the drug binding site in 
the target molecule 31,51. Resistance to ibrutinib has been observed in a small 
number of patients with CLL through acquired mutations in the BTK drug binding site 
and gain of function mutations in the down-stream signalling molecule PLCgamma2 
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52. If ibrutinib shows clinical efficacy in trials in AML it seems likely that similar 
resistance mechanisms will be seen in a subset of the patients treated.  Clinical 
studies will ultimately determine the efficacy and duration of response of ibrutinib 
containing regimens in AML and only thereafter will they establish the frequency of 
drug resistance and its mechanisms. 
 
In summary this study links a common genetic mutation found in AML to a specific 
clinically available downstream kinase (BTK) inhibitor, ibrutinib. Furthermore we 
have identified the potential efficacy of combination therapy with daunorubicin  
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Legends 
Figure 1. Ibrutinib inhibits survival of FLT3-ITD positive AML. Primary AML 
blasts from 5 patients with FLT3-ITD and 6 patients with non FLT3-ITD were treated 
with increasing doses of ibrutinib for 1 hour and then washed and cultured for 72 
hours and then assessed by CellTiterGlo. Data were normalised to DMSO treated 
cells. Line indicates median and *indicates statistical significance of P < 0.05 using 
the Mann-Whitney test comparing ibrutinib treated samples compared to control. (B) 
AML cell lines which were FLT3-ITD (MV4-11) and non FLT3-ITD  (OCI-AML3 and 
THP-1) were treated with increasing doses of ibrutinib for 1 hour and then washed 
and cultured for 72 hours and then assessed by CellTiterGlo. *indicates statistical 
significance using the Mann-Whitney test comparing ibrutinib treated samples 
compared to control. (C) AML blasts and CD34+ control cells were treated with 0, 
500 and 1000 nM of ibrutinib and colony forming assays were performed to show the 
number of colonies In all panels line indicates the median and * indicates statistical 
significance of P < 0.05 between ibrutinib treated groups and control using the Mann-
Whitney test. (D) Untreated primary AML blasts which were FLT3-ITD and non 
FLT3-ITD and (E) untreated AML cell lines were examined for the expression of 
pBTK, total BTK and β-actin. The presented blots were derived from multiple gels. 
The membranes were cut based on molecular weights and probed with the antibody 
of interest 
 
Figure 2. Ibrutinib inhibits downstream FLT3 signalling. (A) Primary AML blasts 
which were FLT3-ITD and non FLT3-ITD were treated with increasing doses of 
ibrutinib for 3 hour and then whole cell extracts were prepared and Western blot 
analysis was conducted for pBTK, BTK. and (B) pAKT, AKT, pMAPK and MAPK 
protein levels. (C) AML cell lines which were FLT3-ITD (MV4-11) and non FLT3-ITD 
(OCI-AML3) were treated with 500nM of ibrutinib for 3 hour and then whole cell 
extracts were prepared and Western blot analysis was conducted for pFLT3, FLT3, 
pAKT, AKT, pMAPK, MAPK, pSTAT and STAT protein levels. The presented blots 
were derived from multiple gels. The membranes were cut based on molecular 
weights and probed with the antibody of interest.  
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Figure 3. Ibrutinib enhances daunorubicin induced apoptosis. (A) FLT3-ITD 
(MV4-11) and non FLT3-ITD (OCI-AML3) cells were treated with 500nM of ibrutinib 
for 1 hour and washed and daunorubicin was added in increasing doses and then 
cultured for 48 hours and then assessed by CellTiterGlo. (B) FLT3-ITD (MV4-11) and 
non FLT3-ITD (OCI-AML3) cells were treated with 500nM of ibrutinib for 1 hour and 
washed and daunorubicin added in increasing doses and then cultured for 24 hours 
and then assessed by annexin V and PI staining. (C) Primary AML (FLT3-ITD) were 
pre-treated with ibrutinib for 1 h and then treated 50nM daunorubicin and then 
cultured for 48 hours on BMSC and then assessed by CD45 and annexin V staining. 
Cells expressed as percent Annexin V positive. *indicates P< 0.05 Mann Whitney 
test comparing the ibrutinib plus daunorubicin to daunorubicin alone treated samples 
 
  
Figure 4. BTK targeted siRNA inhibits survival of MV4-11 but not OCI-AML3.  
(A) FLT3-ITD (MV4-11) and non FLT3-ITD (OCI-AML3) AML cell lines were 
transfected with control siRNA and 4 BTK siRNA and then cultured for 24 h before 
RNA extraction analysis for target gene expression using QRT-PCR. (B) Western 
blot analysis for total BTK in response to transfected control, BTK3 and BTK4 siRNA 
and (C) for pAKT and total AKT in response to transfected control and BTK4 siRNA. 
The presented blots were derived from multiple gels. The membranes were cut 
based on molecular weights and probed with the antibody of interest. (D) FLT3-ITD 
(MV4-11) and non FLT3-ITD (OCI-AML3) cells were transfected with control siRNA 
and BTK siRNA3 and 4 and then cultured for 48 h and then assessed by 
CellTiterGlo. (E) FLT3-ITD (MV4-11) and non FLT3-ITD (OCI-AML3) cells were 
transfected with control siRNA and BTK siRNA3 and then cultured for 24 h and then 
daunorubicin was added in increasing doses and then cultured for a further 48 hours 
and then assessed by CellTiterGlo. *Indicates P< 0.05 Mann Whitney test comparing 
the BTK siRNA transfected samples to control siRNA samples. 
 
 
